Compare CME & BSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CME | BSX |
|---|---|---|
| Founded | 1898 | 1979 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 106.9B | 103.6B |
| IPO Year | 2002 | 2010 |
| Metric | CME | BSX |
|---|---|---|
| Price | $307.67 | $69.74 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 20 |
| Target Price | ★ $295.62 | $106.85 |
| AVG Volume (30 Days) | 2.1M | ★ 10.7M |
| Earning Date | 04-22-2026 | 04-22-2026 |
| Dividend Yield | ★ 3.69% | N/A |
| EPS Growth | 15.41 | ★ 55.20 |
| EPS | ★ 11.16 | 1.94 |
| Revenue | $6,520,600,000.00 | ★ $9,076,000,000.00 |
| Revenue This Year | $8.62 | $12.02 |
| Revenue Next Year | $4.64 | $10.41 |
| P/E Ratio | ★ $27.56 | $35.95 |
| Revenue Growth | 6.37 | ★ 12.49 |
| 52 Week Low | $248.63 | $67.56 |
| 52 Week High | $329.16 | $109.50 |
| Indicator | CME | BSX |
|---|---|---|
| Relative Strength Index (RSI) | 48.80 | 35.16 |
| Support Level | $261.65 | $67.56 |
| Resistance Level | $309.35 | $76.77 |
| Average True Range (ATR) | 5.38 | 1.76 |
| MACD | -1.90 | 0.44 |
| Stochastic Oscillator | 27.52 | 35.10 |
Based in Chicago, CME Group operates exchanges giving investors, suppliers, and businesses the ability to trade futures and derivatives based on interest rates, equity indexes, foreign currencies, energy, metals, and commodities. The Chicago Mercantile Exchange was founded in 1898 and in 2002 completed its IPO. Since then, CME Group has consolidated parts of the industry by merging with crosstown rival CBOT Holdings in 2007 before acquiring Nymex Holdings in 2008 and NEX in 2018. In addition, the company has a 27% stake in S&P Dow Jones Indices, making the Chicago Mercantile Exchange the exclusive venue to trade and clear S&P futures contracts. Through CME's acquisition of NEX, it also expanded into cash foreign exchange, fixed-income trading, and collateral optimization.
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.